author-photo

Rosalind Catchatourian

John H. Stroger, Jr. Hospital of Cook County

31

Papers

212

Citations

Citation Trend

Filter By

Papers (18) Sort By

Journal Conference Others

Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

2018 Blood
Show All
- Source
- Cite
- Save
Citations (33)
Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial

2017 Blood
Show All
- Source
- Cite
- Save
Citations (6)
Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib

2017 Blood
Show All
- Source
- Cite
- Save
Citations (4)
Single-Arm Phase II Trial of Pegylated Interferon Alpha 2a in Patients with High-Risk Essential Thrombocythemia or Polycythemia Vera Resistant or Intolerant to Hydroxyurea: MPN Symptom Impact & Quality of Life Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial

2017 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Geographic variation of extranodal sites of mucosal associated lymphoid tissue lymphoma (MALToma): Analysis of series from two institutions.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
CNS Relapse in Diffuse Large B-Cell Lymphoma Patients with Oral Cavity and Bone Marrow Involvement-Experience from an Inner City Hospital

2016 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Health-related quality of life in underserved patients with hematologic malignancies.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Primary malignant myelomatous pleural effusion.

2016 Clinical Case Reports
Show All
- Source
- Cite
- Save
Citations (3)
Rapid Achievement of MR4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal

2015 Blood
Show All
- Source
- Cite
- Save
Citations (5)
Deep Molecular Response in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Nilotinib: ENESTnext Update

2014 Blood
Show All
- Source
- Cite
- Save
Citations (0)